What are the side effects of venetoclax/venetoclax?

Venetoclax/Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Although its efficacy is significant, it is also associated with various side effects. In the safe population of such diseases, the most common adverse reactions of venetoclax occur in more than 20%, including neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema.

In the treatment of acute myeloid leukemia (ALL), the incidence of adverse reactions is more significant when venetoclax is combined with decitabine, azacitidine, or low-dose cytarabine. In this setting, side effects such as nausea, diarrhea, thrombocytopenia, constipation, neutropenia, pyrexia, neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, bleeding, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, and hypotension may occur in ≥30% of patients.

It can be seen from the above side effects that the use of venetoclax requires careful monitoring of the patient's blood picture changes, especially changes in the number of white blood cells and platelets, to prevent serious infection and bleeding risks. In addition, patients should pay attention to promptly reporting any symptoms of discomfort during treatment so that doctors can adjust the treatment plan in a timely manner.

Overall, although venetoclax has shown good efficacy in the treatment of specific hematological malignancies, its potential adverse reactions also remind us that the patient's overall health status and risk management need to be considered when using it.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018